News and Events

News and Press

Vaxxilon Shares Transferred to Idorsia as part of the J&J Actelion Acquisition
June 16, 2017

Actelion Ltd was the principal investor and majority shareholder of Vaxxilon AG since its inception in June 2015. In association with the Actelion acquisition by Janssen Holding GmbH, an indirect subsidiary of Johnson & Johnson, Actelion carried out a demerger of Actelion’s drug discovery and early clinical pipeline assets into Idorsia, a newly formed company, headquartered in Allschwil, Switzerland. The Vaxxilon shareholding was among these assets.

Peter Seeberger Presents at the Perlen der Forschung für die Anwendung
January 13, 2017

Peter Seeberger had the opportunity to present the science, technology, and global health implications of synthetic carbohydrate vaccines at the scientific forum “Pearls of Research and Their Applications” hosted by Chancellor Angela Merkel.


Source: https://www.bundesregierung.de/

The Royal Society of Chemistry
January 11, 2017

Vaxxilon aims to simplify vaccine development by replacing biological components with well-defined synthetic molecules.


Source: https://www.chemistryworld.com/

Vaxxilon builds management team
August 26, 2016

Vaxxilon AG today announced that Arne von Bonin, PhD has been appointed to the role of Chief Scientific Officer (CSO). Dr. von Bonin is responsible for preclinical and early phase development for Vaxxilon’s multiple projects including the design, implementation and execution of proof of concept and toxicology studies, Phase 1/2 trials and associated regulatory filings.

Max Planck Gesellschaft Wissenschafts – Nachricht
June 26, 2015

Das Unternehmen Impfstoffe

Die Max-Planck-Gesellschaft und Actelion gründen das Start-up-Unternehmen Vaxxilon, um Kohlenhydrat-basierte Impfstoffe zu kommerzialisieren

ACTELION PRESS RELEASE

Actelion creates Vaxxilon together with the Max Planck Society ALLSCHWIL, SWITZERLAND – 26 June 2015 – Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic carbohydrate vaccines.


Source: Max Planck Gesellschaft

Events

VPM – 10th International VPM Days
TWINCORE in Hannover, Germany | September 14, 2017

10th International VPM Days “15 Years VPM - from Target to Market” to be held on September 14 – 15, 2017 at the TWINCORE in Hannover, Germany
Further Details

Presentations

Vaxxilon – Falling Walls Science Start-up of the Year 2016

nominated by Max Planck Innovation Munich presented by CEO Tom Monroe

Further Details

Basel Area Vaxxilon AG Christoph Merian-Ring 11, 4153 Reinach, Switzerland

Berlin Area (Adlershof) Vaxxilon Deutschland GmbH Magnusstraße 11, 12489 Berlin, Germany